| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
S130 causes increased cytotoxicity by blocking ATG4B, which in turn stops autophagy and triggers apoptosis [1]. S130 (10 μM; 6 hours) suppresses autophagy in late autolysosomal degradation or early LC3 initiation [1]. More lipidated LC3 is accumulated in autolysosomes by S130 [1]. At doses greater than 6.3 μM, ATG4B activity is inhibited by S130 (0-25 μM; 48 hours), which results in cell death. Also, necroptosis—the process by which cells die—may not result from this cytotoxicity [1]. S130-induced cytotoxicity is increased by malnutrition [1]. S130 (0-10 μM; 24 hours) prevented ATG4B KO cells from cleaving full-length LC3-GST by roughly 79% at 10 μM without consuming any substrate. The effect of S130 on ATG4B is strongly inhibitory [1].
|
|---|---|
| ln Vivo |
In vivo, S130 (20 mg/kg; intraperitoneal injection; daily; 3-week duration) effectively suppresses tumor development and exhibits anti-tumor effects while maintaining a favorable safety profile for critical organs [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: HeLa cells, HCT116 cells, HL60 cells Tested Concentrations: 0 μM, 3.1 μM, 6.3 μM, 12.5 μM, 25 μM Incubation Duration: 48 hrs (hours) Experimental Results: Significant cytotoxic effect on HeLa cells (IC50 = 16.1 µM), HCT116 cells (IC50 = 9.0 µM) and HL60 cells (IC50 = 4.7 µM) at doses above 6.3 µM. And this cytotoxicity may not lead to cell death via necroptosis. Autophagy assay [1] Cell Types: HeLa cells and MEF cells Tested Concentrations: 10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Inhibition of autophagy in the early stage of LC3 initiation or late stage of autolysosomal degradation. Western Blot Analysis[1] Cell Types: HeLa Cell Tested Concentrations: 0 μM, 5 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: 10 μM inhibited ~79% cleavage of full-length LC3-GST with no substrate in ATG4B KO processed in cells. |
| Animal Protocol |
Animal/Disease Models: BALB/c female nude mice (4 weeks), HCT116 cell xenotransplantation [1]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; 3 weeks Experimental Results: able to inhibit tumor growth and have effects on important organs Good security. |
| References |
| Molecular Formula |
C24H25N3O2
|
|---|---|
| Molecular Weight |
387.474205732346
|
| Exact Mass |
387.194
|
| CAS # |
1160852-22-1
|
| PubChem CID |
44128205
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C=CC=CC=2C2C=CC=C3C(=CN=C1C=23)C(NCCCN(CC)CC)=O
|
| InChi Key |
DZUCZYXRADUTMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H25N3O2/c1-3-27(4-2)14-8-13-25-24(29)20-15-26-22-21-17(11-7-12-18(20)21)16-9-5-6-10-19(16)23(22)28/h5-7,9-12,15H,3-4,8,13-14H2,1-2H3,(H,25,29)
|
| Chemical Name |
N-[3-(diethylamino)propyl]-8-oxo-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17),14-octaene-12-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~322.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5808 mL | 12.9042 mL | 25.8084 mL | |
| 5 mM | 0.5162 mL | 2.5808 mL | 5.1617 mL | |
| 10 mM | 0.2581 mL | 1.2904 mL | 2.5808 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
